Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.36 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | PON1 | P27169 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22149740 | 1.00 | CA1 (0.44) | CA1CA9MAPTSMN1; SMN2KDM4E | |
| SCHEMBL22149723 | 0.81 | MEN1 (0.44) | CA9MAPTSMN1; SMN2KDM4EKMT2A | |
| SCHEMBL22149253 | 0.81 | MEN1 (0.44) | CA9MAPTSMN1; SMN2KDM4EKMT2A | |
| SCHEMBL22149509 | 0.78 | MAPT (0.44) | CA1CA9MAPTSMN1; SMN2KDM4E | |
| SCHEMBL22149518 | 0.78 | MAPT (0.44) | CA1CA9MAPTSMN1; SMN2KDM4E | |
| SCHEMBL22149256 | 0.78 | MAPT (0.44) | CA1CA9MAPTSMN1; SMN2KDM4E | |
| SCHEMBL24264467 | 0.77 | ALDH1A1 (0.42) | MAPTSMN1; SMN2KDM4EKMT2AALDH1A1 | |
| SCHEMBL22149725 | 0.77 | KDM4E (0.42) | CA1CA9MAPTKDM4EALDH1A1 | |
| SCHEMBL22149507 | 0.77 | TAS1R3 (0.36) | TAS1R3TAS1R1HCAR2 | |
| SCHEMBL22149566 | 0.76 | CYP2A6 (0.34) | CA1MAPTALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3898613-B1 | ANTICANCER COMPOUNDS | PHARMA MAR SA (ES) | 2023-08-09 | — | — | EP | disclosed |
| US-20220056021-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A. (ES) | 2022-02-24 | — | — | US | disclosed |
| WO-2020127194-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A. (ES) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056021-A1 | ANTICANCER COMPOUNDS | TP53, MCL1, MYC | CA1 3322/4885CA9 768/4885MAPT 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.